Sphera Funds Management’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.72M | Sell |
603,377
-55,000
| -8% | -$788K | 1.39% | 14 |
|
|
2025
Q4 | $9.38M | Sell |
658,377
-332,765
| -34% | -$3.27M | 1.81% | 12 |
|
|
2025
Q3 | $7.81M | Buy |
991,142
+424
| +0% | +$3.02K | 1.65% | 14 |
|
|
2025
Q2 | $5.68M | Buy |
+990,718
| New | +$6.39M | 1.33% | 24 |
|
|
2022
Q3 | – | Sell |
-753,037
| Closed | -$8.09M | – | 80 |
|
|
2022
Q2 | $8.09M | Buy |
+753,037
| New | +$6.2M | 0.87% | 26 |
|
|
2021
Q4 | – | Sell |
-491,159
| Closed | -$4.69M | – | 106 |
|
|
2021
Q3 | $4.69M | Buy |
+491,159
| New | +$5.02M | 0.39% | 70 |
|
|
2021
Q1 | – | Sell |
-265,753
| Closed | -$6.14M | – | 182 |
|
|
2020
Q4 | $6.14M | Sell |
265,753
-977,797
| -79% | -$20M | 0.54% | 57 |
|
|
2020
Q3 | $17.6M | Sell |
1,243,550
-385,000
| -24% | -$5.61M | 1.73% | 15 |
|
|
2020
Q2 | $24.6M | Sell |
1,628,550
-389,074
| -19% | -$4.74M | 2.31% | 12 |
|
|
2020
Q1 | $18.6M | Sell |
2,017,624
-782,696
| -28% | -$7.44M | 2.33% | 12 |
|
|
2019
Q4 | $27.3M | Sell |
2,800,320
-130,000
| -4% | -$1.19M | 2.25% | 10 |
|
|
2019
Q3 | $23.5M | Buy |
2,930,320
+420,000
| +17% | +$4.56M | 3.63% | 7 |
|
|
2019
Q2 | $31.3M | Buy |
2,510,320
+22,242
| +0.9% | +$282K | 4.29% | 6 |
|
|
2019
Q1 | $33.8M | Buy |
2,488,078
+40,084
| +2% | +$490K | 3.09% | 4 |
|
|
2018
Q4 | $23.5M | Buy |
2,447,994
+660,000
| +37% | +$7.25M | 2.64% | 8 |
|
|
2018
Q3 | $21.6M | Buy |
1,787,994
+598,938
| +50% | +$8.38M | 2.48% | 8 |
|
|
2018
Q2 | $18.6M | Sell |
1,189,056
-656,648
| -36% | -$9.93M | 2.56% | 11 |
|
|
2018
Q1 | $27.8M | Buy |
1,845,704
+745,704
| +68% | +$11.3M | 4.21% | 5 |
|
|
2017
Q4 | $15.8M | Buy |
1,100,000
+680,000
| +162% | +$9.34M | 1.86% | 9 |
|
|
2017
Q3 | $6.33M | Buy |
420,000
+20,000
| +5% | +$265K | 0.9% | 25 |
|
|
2017
Q2 | $4.03M | Sell |
400,000
-100,000
| -20% | -$805K | 0.68% | 45 |
|
|
2017
Q1 | $3.56M | Sell |
500,000
-230,000
| -32% | -$1.45M | 0.7% | 40 |
|
|
2016
Q4 | $3.63M | Sell |
730,000
-175,000
| -19% | -$1.21M | 0.92% | 33 |
|
|
2016
Q3 | $6.7M | Sell |
905,000
-100,000
| -10% | -$675K | 1.09% | 20 |
|
|
2016
Q2 | $5.49M | Buy |
1,005,000
+705,000
| +235% | +$4.93M | 1.42% | 15 |
|
|
2016
Q1 | $2.54M | Buy |
+300,000
| New | +$2.12M | 0.55% | 34 |
|
|
2015
Q4 | – | Sell |
-310,000
| Closed | -$4.34M | – | 123 |
|
|
2015
Q3 | $4.34M | Sell |
310,000
-140,000
| -31% | -$2.2M | 0.55% | 32 |
|
|
2015
Q2 | $6.37M | Hold |
450,000
| – | – | 0.62% | 31 |
|
|
2015
Q1 | $4.9M | Sell |
450,000
-100,000
| -18% | -$881K | 0.51% | 43 |
|
|
2014
Q4 | $4.58M | Buy |
+550,000
| New | +$3.77M | 0.78% | 39 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Sphera Funds Management's FOLD Position: Q1 2026 in Review
Sphera Funds Management reduced its Amicus Therapeutics (FOLD) stake by 8.4% in Q1 2026, selling an estimated $788K and leaving 603,377 shares worth $8.72M. The position accounts for 1.39% of the portfolio, ranked #14.
Sphera Funds Management first reported a position in FOLD in Q4 2014 and has held it in 30 quarters since. The position peaked at $33.8M in Q1 2019. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Sphera Funds Management held 603,377 shares of Amicus Therapeutics worth $8.72M as of Q1 2026.
- Sphera Funds Management sold 55,000 Amicus Therapeutics shares in Q1 2026, an estimated $788K.
- Amicus Therapeutics made up 1.39% of Sphera Funds Management's portfolio in Q1 2026, its #14 holding.
- Sphera Funds Management first reported a position in Amicus Therapeutics in Q4 2014 and has held it in 30 quarters since.
- Sphera Funds Management's Amicus Therapeutics position peaked at $33.8M in Q1 2019.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.